An update from Deciphera Pharmaceuticals (DCPH) is now available.
Following the merger on June 11, 2024, Deciphera has made significant changes including the termination of various equity and stock plans, the resignation of several board members, and the appointment of new ones. Additionally, the company has amended its certificate of incorporation and by-laws, notified Nasdaq to suspend trading, and intends to cease its reporting obligations. Furthermore, Deciphera has canceled its upcoming Annual Meeting of Stockholders originally scheduled for June 20, 2024.
See more data about DCPH stock on TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
